TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
16 Avril 2024 - 10:25PM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage
biopharmaceutical company focused on the development of T cell
receptor (TCR)-engineered T cell therapies (TCR-T) for the
treatment of patients with cancer, today announced that it has
commenced an underwritten public offering of $125 million of shares
of its voting common stock and, in lieu of voting common stock, to
certain investors that so choose, pre-funded warrants to purchase
shares of voting common stock. All shares of voting common stock
and pre-funded warrants to be sold in the offering will be offered
by TScan. TScan intends to grant the underwriters a 30-day option
to purchase additional shares of its voting common stock in an
amount equal to 15% of the securities offered in the public
offering. The offering is subject to market, regulatory and other
conditions and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Morgan Stanley and TD Cowen are acting as joint
book-running managers for the offering. LifeSci Capital is acting
as Lead Manager, and BTIG, H.C. Wainwright & Co. and
Needham & Company are each acting as co-managers for the
offering.
The Company intends to use the net proceeds from
the offering for general corporate purposes.
A registration statement on Form S-3 (File No.
333-277699) relating to these securities was filed with the
Securities and Exchange Commission (the SEC) on March 6, 2024, and
was declared effective by the SEC on April 12, 2024. The offering
was made only by means of a preliminary prospectus supplement and
accompanying filed with the SEC. A final prospectus supplement and
accompanying prospectus relating to the offering will also be filed
with the SEC. These documents will be available for free on the
SEC’s website at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the
offering, when available, may be obtained from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, New York 10014, telephone: (866)
718-1649 or by emailing prospectus@morganstanley.com, or TD
Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by
telephone at (855) 495-9846 or by email at
TD.ECM_Prospectus@tdsecurities.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About TScan Therapeutics,
Inc.
TScan is a clinical-stage biopharmaceutical
company focused on the development of T cell receptor
(TCR)-engineered T cell therapies (TCR-T) for the treatment of
patients with cancer. The Company’s lead TCR-T candidates, TSC-100
and TSC-101, are in development for the treatment of patients with
hematologic malignancies to prevent relapse following allogeneic
hematopoietic cell transplantation. The Company is also developing
multiplexed TCR-T candidates for the treatment of various solid
tumors. The Company has developed and continues to expand its
ImmunoBank, the Company’s repository of therapeutic TCRs that
recognize diverse targets and are associated with multiple HLA
types, to provide customized multiplex therapeutic TCR-Ts for
patients with a variety of cancers.
Forward-Looking Statements
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements related to
TScan’s ability to complete the financing and its use of proceeds.
These and other risks are discussed in TScan’s filings with the
SEC, including, without limitation, its most recent Annual Report
on Form 10-K, and its periodic reports on Form 8-K, as well as the
risks identified in the registration statement and the preliminary
prospectus supplement relating to the offering. TScan intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. In some cases, you can identify
forward-looking statements by terms such as, but not limited to,
“may,” “might,” “advance,” “will,” “objective,” “intend,” “should,”
“could,” “can,” “would,” “expect,” “believe,” “anticipate,”
“project,” “target,” “design,” “estimate,” “predict,” “potential,”
“plan,” “on track,” or similar expressions or the negative of those
terms. Such forward-looking statements are based upon current
expectations that involve risks, changes in circumstances,
assumptions, and uncertainties. Any forward-looking statements
contained in this release represent TScan’s views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Except as required by law, TScan
explicitly disclaims any obligation to update any forward-looking
statements.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor
Relations857-399-9840hsavelle@tscan.com
Melissa ForstArgot
Partners212-600-1902TScan@argotpartners.com
TScan Therapeutics (NASDAQ:TCRX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
TScan Therapeutics (NASDAQ:TCRX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024